Oncolytics Biotech (NASDAQ:ONCY) Earns Buy Rating from HC Wainwright

Oncolytics Biotech (NASDAQ:ONCY)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 385.44% from the company’s previous close.

Oncolytics Biotech Trading Down 8.0 %

Oncolytics Biotech stock opened at $1.03 on Thursday. The stock has a 50-day moving average price of $1.08 and a two-hundred day moving average price of $1.06. Oncolytics Biotech has a 12 month low of $0.84 and a 12 month high of $1.75. The company has a market capitalization of $79.38 million, a PE ratio of -3.81 and a beta of 1.69.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent filing with the Securities and Exchange Commission. 6.82% of the stock is owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.